Copyright ©The Author(s) 2021.
World J Clin Oncol. Jul 24, 2021; 12(7): 557-564
Published online Jul 24, 2021. doi: 10.5306/wjco.v12.i7.557
Table 1 Relevant characteristics of current available neoadjuvant and perioperative therapies for esophagogastric junction tumors
StudyYearNumber of patientsIncluded patientsGroupsEGJ tumors Outcomes
MAGIC2006503Gastric, lower esophagus, and EGJ tumorsECF + Surgery vs Surgery alone11% Perioperative chemotherapy improves overall survival
ACCORD2011224Gastric, lower esophagus and EGJ tumorsCF + Surgery vs Surgery alone64% Perioperative chemotherapy improves overall survival, disease-free survival and resecability
CROSS2012366Esophageal and EGJ tumorsChemoradiation + Surgery vs Surgery alone22%Chemoradiotherapy improves overall survival
FLOT2019716Gastric and EGJ tumorsFLOT vs ECF56%FLOT improves overall survival
Table 2 Potential advantages (+) and disadvantages (-) of preoperative chemoradiation and perioperative chemotherapy
Preoperative chemoradiotherapyPerioperative chemotherapy
+ Better loco-regional control+ Better systemic control
+ High rates of complete pathologic response+ No adverse events from radiotherapy
- Poorer response in adenocarcinoma (increased radiation sensitivity in squamous cell carcinoma)- Poorer loco-regional control
- Radiation-induced changes in surgical field- Many patients are not able to complete the postoperative regimen